CD8A and cancer: Firstly, it was expected that we found monocyte-to-DC differentiation to be significantly higher at the early stage of therapy for NSCLC patients, given this differentiation is known to attenuate CD8 + T cell response and predict clinical outcomes of patients with other cancers [39–41].